Lynx1 Capital Management LP 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:19 am Sale |
2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 46 0.100% |
-114,511 (-99.96%) |
Filing |
| 2022-12-30 4:29 pm Purchase |
2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Lynx1 Capital Management LP | 114,557 5.380% |
114,557 (New Position) |
Filing |